Last checked at 1 Aug 2014 10:58
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- Stock Screeners
- Share Chat
- FX
- News & RNS
- Events
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Avacta Group Share News (AVCT)
AVCT Share
Price
AVCT Share
News2
AVCT Share
Chat66
AVCT Share
Trades145
AVCT
Live RNS
AVCT Share
Charts
AVCT Level 2
Console
AVCT Live
Share Price
AVCT Broker
Ratings
AVCT Directors
Deals
AVCT Financial
Diary
AVCT
Fundamentals
AVCT Short
Positions1
AVCT
Media
Avacta Group Information
Share Price Information for Avacta Group (AVCT)
Share Price is delayed by 15 minutes
Get Live Data
Share Price:
40.00
Bid:
39.50
Ask:
40.50
Change:
0.00 (0.00%)
Spread:
1.00 (2.532%)
Open:
40.00
High:
41.25
Low:
40.00
Prev. Close:
40.00
Last checked at -
Watchlists are a member only feature
Login to your account
Don't have an account? Click here to register.Avacta expects licensing deal for therapeutics product in 2017, order book swells
Fri, 20th Jan 2017 10:17
(ShareCast News) - Life science firm Avacta expects to have its first licensing deal for Affirmer, its biotherapeutics product, this year as its order book swelled.In an update for the six months ended 31 January, the the company said that its order book for Affimer grew 70% year-on-year, which along with paid-for commercial evaluations could lead to to licensing deals in 2017.The company said it is undergoing multiple paid-for commercial technology valuations with four large pharmaceutical firms, over 10 biotech companies, eight tools companies and several diagnostics firms, while its Affirmer technology has already been granted a patent in Europe.It's half-year revenue, operating losses and cash balances are in line with market forecasts.Avacta's in-house therapeutic development programme saw positive results from the first in vivo studies that demonstrated efficacy, tolerability and suitable pharmacokinetics properties of Affimer molecules, which the companies believes "de-risks the platform considerably". The company is targeting 2019 for the programme to make to clinics.Chief executive, Dr Alastair Smith, said the company's collaborations with partners such as Moderna, Glythera and the Memorial Sloan Kettering Cancer Centre, which will generate Affimer proof of concept data later in 2017, provides additional opportunities to develop therapeutic applications of the Affimer technology.He added: "With our expectation of strong news flow to underpin increasing shareholder value this year, we start 2017 with great enthusiasm."Shares in Avacta were down 1.37% to 72p at 1026 GMT.
More News
1 Aug 2014 10:33
Friday broker round-up UPDATE
AstraZeneca: Deutsche Bank ups target price from 3950p to 4000p staying with its hold recommendation. Avacta: Numis places both its target price and its buy recommendation under review. Barclays: Berenberg upgrades from sell to hold with a target price of 220p. Bodycote: UBS shifts target price f
Read more23 Jul 2014 14:17
Sector movers: Weak results, outlook from Glaxo sink pharma stocks
A slump in the share price of GlaxoSmithKline dragged the pharmaceuticals and biotechnology sector into the red on Wednesday as the drugmaker disappointed with a drop in quarterly sales and its full-year outlook. The company announced at midday that it has slashed its 2014 outlook as it reported a
Read more4 Jun 2014 09:28
Wednesday broker round-up UPDATE
Advanced Computer Software: Panmure Gordon ups target price from 139p to 155p and stays with its buy recommendation. Avacta: Numis shifts target price from 1.9p to 2p and retains a buy recommendation. Balfour Beatty: Westhouse Securities reduces target price from 302p to 220p keeping its neutral r
Read more4 Jun 2014 09:07
UK BROKER RATINGS: Morgan Stanley Cuts SABMiller To Equal-Weight
LONDON (Alliance News) - The following UK shares received analyst recommendations Wednesday morning:
----------
FTSE 100
----------
NOMURA RAISES REED ELSEVIER PRICE TARGET TO 1050 (975) PENCE - 'BUY'
----------
CITIGROUP CUTS TULLOW OIL PRICE TA
2 Jun 2014 09:04
Avacta Gets Funding Award To Support Affirmer Development
LONDON (Alliance News) - Avacta Group PLC Monday said it had secured a funding award from the UK's innovation agency to support it in developing affirmer technology as a potential way of helping develop new cancer treatments. The company is developing affimers, which are engineered alternat
Read more9 May 2014 10:34
Avacta In Collaboration Deal With UbiQ To Develop Ubiquitin Reagents
LONDON (Alliance News) - Avacta Group PLC Friday said it has signed a collaboration deal with ubiquitylated peptides supplier UbiQ Bio under which the companies will work together to develop reagents that specifically bind to ubiquitin chains. Avacta makes diagnostic tools, consumables and
Read more9 May 2014 08:30
Avacta collaborates with UbiQ Bio
AIM-listed pharmaceuticals company Avacta Group announced it has signed a collaboration deal with proteins provider UbiQ Bio to build up its chain of ubiquitin Affimers. The group will be providing Avacta with small proteins found in humans and animals to further the firm's development of Affimers
Read more7 May 2014 10:18
REPEAT: Avacta Raises GBP10.1M In Placing With Additional Option
LONDON (Alliance News) - Avacta Group PLC Wednesday said it has raised GBP10.1 million before expenses through a share placing on 918.2 million shares, which it will use to accelerate the development and commercialisation of Affimers. The shares were placed with both new and existing instit
Read more7 May 2014 10:16
Avacta Raises GBP10.1M In Share Placing With Additional Option
LONDON (Alliance News) - Avacta Group PLC Wednesday said it has raised GBP10.1 million before expenses through a share placing on 918.2 million shares, which it will use to accelerate the development and commercialisation of Affimers. The shares were placed with both new and existing instit
Read more23 Apr 2014 12:13
Avacta Loss Narrows, Boosted By Sales Of Analytical Instrument Optim
LONDON (Alliance News) - Avacta Group PLC Wednesday posted a narrowed pretax loss for the year to end-January, boosted by increased sales of its analytical instrument Optim. The biotechnology company posted a pretax loss of GBP500,000, narrowed from GBP807,000 in the previous year, as reven
Read more23 Apr 2014 05:08
UK Earnings, Trading Statements Calendar - Week Ahead
| UK Earnings, Trading Statements Calendar | |
Read more
Login to your accountDon't have an account? Click here to register.Quickpicks are a member only featureLogin to your accountDon't have an account? Click here to register. |